Morbidity and Mortality Weekly Report (MMWR)

This report describes opioid prescribing patterns preceding overdose deaths in Pennsylvania that included a contributing opioid, stimulant, or both.

This report describes a fatal Lassa fever case in a patient returning form Liberia.

This report describes a community cohort study on the average incidence of symptomatic human metapneumovirus infection in Oregon and Washington.

This report describes co-circulation of human metapneumovirus and respiratory syncytial virus.

This report describes a fatal case of Acanthamoeba infection associated with using tap water in an electronic nasal irrigation device and a CPAP machine at home.

This report describes an analysis of synthetic opioid and stimulant co-involved overdose deaths by occupations and industries.

This report describes a fatal case of Naegleria fowleri infection associated with a splash pad in Arkansas.

This report describes the annual rate of newly reported chronic hepatitis C among adults in Alaska.

This report describes adolescent girls and young women with functional disabilities had who higher prevalence of experiencing sexual, physical and emotional violence.

This report describes a case of rhodesiense human African trypanosomiasis among a U.S. traveler returning from Zimbabwe.

This report describes management of tuberculosis (TB) risk among household contacts of people living with TB.

This report describes neurosyphilis, ocular syphilis, and otic syphilis cases in Chicago during January 1-October 31, 2023.

This report describes cases of highly pathogenic avian influenza detected among 38 people in California.

This report describes traffic-related deaths rates in the U.S. and 27 high-income countries.

This report describes vaccine-derived poliovirus type 2 detected in wastewater samples in 16 cities in five European countries.

This report describes a decrease in the number of adults who exclusively smoke cigarettes and an increase in the number who exclusively use e-cigarettes.

This report describes tobacco use among Medicaid members during 2016-2023.

This report describes idiopathic pulmonary fibrosis deaths among U.S. workers by industry and occupation.

This report describes the percentage of adults with chronic pain in the past three months.

This report describes deaths attributed to excessive cold or hypothermia by month.

This report describes an analysis of Oregon wastewater surveillance data that detected avian influenza A(H5) in communities with no concurrent outbreaks from dairy facilities or dairy farms.

This report describes decreases in cervical precancer incidence among women ages 20-24 years.

This report describes 2024-2025 COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care encounters.

This report describes cases of influenza-associated encephalopathy or encephalitis among children during 2010-11 through 2024-25 flu seasons.

This report describes interim 2024-2025 seasonal flu vaccine effectiveness estimates in outpatient settings and against flu-associated hospitalizations.

This report describes an increase in particulate matter lead levels in Los Angeles, California during the January 2025 fires.

This report describes significant increase in hepatitis A virus (HAV) wastewater concentrations during an HAV outbreak in Los Angeles County, California.

This report describes highly pathogenic avian influenza virus infection among two indoor cats living in homes of dairy workers.

This report describes a local public health emergency triggered by dengue cases in Puerto Rico during 2024.

This report describes evidence of recent highly pathogenic avian influenza infection among three veterinary practitioners.

This report describes the first reported case of clade Ib monkeypox virus infection in the United States.

This report describes concentrations of perfluoroalkyl and polyfluoroalkyl substances among Maui County, Hawaii employees one month after the 2023 Maui wildfires.

This report describes wildfire-associated emergency department encounters immediately after the 2025 Los Angeles County wildfires.

This report describes CDC's 2025 immunization schedule for children and adolescents aged 18 years or younger.

This report describes barriers to health care providers seeking mental health care during the COVID-19 pandemic.

This report describes CDC's 2025 immunization schedule for adults aged 19 years and older.

This report describes health center visit rates by adults with mental health disorder, substance use disorder, or both

This report describes cases of adverse health effects after ingestion of Diamond Shruumz-brand chocolate bars.

This report describes mercury exposures among workers at an Ohio electronics waste and lamp recycling facility.

This report describes CDC's updated pneumococcal conjugate vaccine recommendation for all adults aged >=50 years who are PCV-naive or who have unknown vaccination history.

This report describes an outbreak of blastomycosis among workers at a paper mill in Michigan.

This report describes an increase in Tularemia cases in 2011-2022 compared to 2001-2010.

This report describes Mycoplasma pneumoniae infections among students and staff of a large public school district in Missouri.

This report describes the percentage of people injecting illegally manufactured fentanyl by route of administration.

This report describes adults with Long COVID and reported limitations performing daily activities.

This report describes a decrease in reporting of human adenoviruses cases to the National Adenovirus Type Reporting System since the COVID-19 pandemic.

This report describes mental health treatment trends among adults.

This report describes CDC's updated recommendations for the MenB-4C vaccine to align the dosing interval and schedule with the new FDA label.

This report describes progress towards eliminating wild poliovirus type 1 in Afghanistan.

This report describes CDC's recommendation that all people aged >=65 years and people ages 6 months-64 years with moderate or severe immunocompromise receive a second 2024-2025 COVID-19 vaccine dose 6 months after their last dose.